ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Dr. Hilmar Ebersbach as Vice President Antibody Development and Protein Engineering (ADPE). Dr. Ebersbach joins ImmunOs from Novartis Pharma, where he served as Group Head with increasing […]
Read MoreAutor: Firma ImmunOs Therapeutics
ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors. Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently […]
Read MoreImmunOs Therapeutics schließt Serie B Finanzierung in Höhe von US $74 Millionen ab
. – Samsara, Lightspeed, Gimv und Mission BioCapital stärken als neue Anteilseigner das Investorenkonsortium und erweitern die transatlantische Präsenz – Unternehmen gründet US-Niederlassung zum Ausbau der internationalen Geschäftstätigkeit ImmunOs Therapeutics AG, ein biopharmazeutisches Unternehmen, das mit seiner HLA-basierten Technologieplattform neuartige Therapeutika zur Behandlung von Krebs- und Autoimmunerkrankungen entwickelt, gab heute den Abschluss einer überzeichneten Serie […]
Read MoreImmunOs Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that the Company will present a scientific poster at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) which will be held November 10-14, 2021, in Washington, DC, USA. […]
Read MoreImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases
– ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific […]
Read More